Lv1
40 积分 2026-07-30 加入
A Randomized Phase Ii Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck (Optim; Aio-Kht-0117)
1个月前
已完结
Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer
1个月前
已完结
Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial
1个月前
已完结
皖公网安备34019202002308
